Key Takeaways
- The DEA opened registration for cannabis manufacturers, distributors, and labs using Form 225 as of October 5.
- This change formalizes a process for operators, providing specific fields tailored to their business activities.
- Registration fees include $3,699 for manufacturers, $1,850 for distributors, and $296 for labs, all payable upon submission.
- Registering grants access to Schedule III benefits, such as Section 280E tax relief, but requires detailed disclosures and comes with risks.
- Operators must weigh the benefits of registration against the need for federal compliance, seeking legal counsel before submitting applications.
Five months after the DEA said dedicated registration options were on the way, the agency has now followed through. State-licensed manufacturers, distributors, and testing labs can now file for Schedule III registration through Form 225, giving the entire cannabis supply chain the same federal on-ramp dispensaries got back in April.
We covered this story in May, when DEA first signaled that manufacturer, distributor, and lab forms were coming while businesses could use the existing Form 225 in the meantime. That wait is over. What’s worth examining now isn’t just that the portal opened, but what it actually asks of operators and whether rushing to register is the right call for every business.
What Changed on October 5
DEA’s Diversion Control Division launched the updated application process for three license categories: manufacturers, who cultivate, produce, process, package, and label cannabis; distributors, who receive and transfer it; and analytical labs, who test it. All three now register under Form 225, selecting the Schedule III Non-Narcotic business activity.
Medical cannabis dispensaries aren’t affected by this update. They continue using Form 224M, the dedicated dispensary application that opened back in late April. That form already went through its own 60-day expedited window, which closed in June.
This expansion fills a gap that existed since the original Schedule III order. Manufacturers and distributors had access to Form 225 months ago, but only as a generic workaround. The portal now formally routes them through a process built around their specific business activities, including fields for state license numbers, business activity type, and the substances they handle.
Businesses that already filed under the generic Form 225 before October 5 don’t need to resubmit. DEA says it will reach out directly to continue processing those applications, so there’s no need to duplicate paperwork if you got ahead of this.
How the Registration Process Actually Works
Form 225 breaks down into six sections: personal and business information, email verification, business activity and schedule, state license details, background information, and payment. It’s a more involved process than a quick online form, and the background section is where most applicants will want to slow down.
That section asks whether the applicant, or any officer, partner, or stockholder, has ever been convicted of a controlled substance crime, had a federal or state registration revoked or suspended, or faced exclusion from a Medicare or state health program. Answering yes means providing dates, locations, and written explanations.
Registration fees vary by license type. Manufacturers pay $3,699 annually, distributors pay $1,850, and analytical labs pay $296. These are nonrefundable and due at submission, payable only by major credit card. That payment requirement creates its own friction, since Visa and Mastercard both prohibit their cards from being used for cannabis transactions, a policy that hasn’t changed even under Schedule III.
DEA’s registration page also includes a direct warning: under 21 U.S.C. 843(d), knowingly submitting false information on the application carries up to four years in prison and a $250,000 fine. That’s not boilerplate. It’s a reminder that this process is being taken seriously on the enforcement side.
Why Schedule III Status Actually Matters
Rescheduling medical cannabis from Schedule I to Schedule III unlocks Section 280E tax relief, the Internal Revenue Code provision that otherwise blocks businesses trafficking in Schedule I or II substances from deducting ordinary expenses like payroll, rent, and utilities. For operators who’ve spent years taxed on gross revenue instead of net profit, that’s a meaningful shift.
Schedule III status also carries federal recognition that cannabis has currently accepted medical use, something that was legally impossible under Schedule I. Congressional researchers have said businesses need to register with DEA to be considered Schedule III compliant, though the details of what that means in practice are still being worked out.
It’s worth remembering what this doesn’t cover. Recreational cannabis stays in Schedule I. Unlicensed bulk marijuana and synthetic THC aren’t included either. This registration pathway is built exclusively for state-licensed medical cannabis businesses and FDA-approved cannabis products.
Should You Hand the Federal Government Your Business Records?
Here’s where some healthy skepticism is warranted. This application asks operators to disclose detailed business information, ownership structures, and criminal history, all under penalty of perjury, to the same federal government that criminalized cannabis for decades and still allows people to serve lengthy sentences for activities large multi-state operators now profit from legally.
That context doesn’t mean registration is the wrong move. For many operators, the 280E tax relief alone makes the math worthwhile, and continuing to do business with other registered supply chain partners may depend on it. But it does mean reading every question on that background section carefully, understanding exactly what you’re disclosing, and talking to counsel before you submit anything.
The DEA’s registration framework leans heavily on state licensing systems already in place, which cuts down on duplicate compliance work. Still, federal registration is a different relationship than a state license. It comes with federal background checks, federal enforcement authority, and federal recordkeeping that didn’t exist for most operators a year ago. Moving carefully isn’t paranoia. It’s just reading the room correctly.
Where This Leaves the Industry
The manufacturer, distributor, and lab portal opening is a real step toward a functional federal framework for medical cannabis, even if it raises as many questions as it answers. Supply chain businesses now have the same concrete filing path dispensaries received in April, closing a gap that had left much of the industry in limbo since spring.
Bigger questions remain unresolved. The broader rescheduling hearing covering all marijuana, not just state-licensed medical products, has faced delays and legal challenges throughout the year. Until that process concludes, recreational cannabis stays locked in Schedule I regardless of how many manufacturers and labs register under this new pathway.
For now, operators handling medical cannabis have a real decision to make: register and access 280E relief with eyes open about what that discloses, or wait and watch how enforcement unfolds for early filers. Either way, it’s worth working with legal counsel before submitting anything to Form 225.
Frequently Asked Questions
Medical cannabis manufacturers, distributors, and analytical labs register under Form 225 as of October 5. Dispensaries use the separate Form 224M application instead.
Manufacturers pay $3,699 annually, distributors pay $1,850 annually, and analytical labs pay $296 annually. All fees are nonrefundable and due at submission.
No. DEA has said it will contact those applicants directly to continue processing their existing submissions rather than requiring a new filing.
No. This registration pathway applies only to state-licensed medical cannabis and FDA-approved cannabis products. Recreational cannabis remains a Schedule I controlled substance under federal law.
Registration requires disclosing detailed business information, ownership structures, and criminal background history under penalty of perjury. Knowingly submitting false information carries penalties of up to four years in prison and a $250,000 fine under 21 U.S.C. 843(d).
